NCCN Guidelines® Insights - Melanoma, Version 4.2014
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Melanoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician